Stimulation of PXR may have clinical possibility, not only because of its capacity to limit inflammation, but also because such an action may improve bone mineralization [40, 41] and bone mineralization is a problem in inflammatory bowel disease [42, 43], whereas the lipophilic ligands used for PXR stimulation may conceivably also have chemopreventive effects with respect to the development of IBD-associated colorectal cancer [44]. This evidence concerns the gene NR1I2 and inflammatory bowel disease.